RETRACTED ARTICLE: Norcantharidin modulates miR-655-regulated SENP6 protein translation to suppresses invasion of glioblastoma cells
- 1.3k Downloads
Norcantharidin (NCTD) is currently used as an anticancer drug for the treatment of some malignant cancers. However, whether it may have therapeutic effects on glioblastoma multiforme (GBM) remains unknown. Moreover, the underlying mechanisms have not been completely elucidated. Recently, SUMO-specific protease 6 (SENP6) has been shown as a tumor suppressor in some cancers. Nevertheless, whether it is involved in the pathogenesis of GBM has not been examined. Here, we studied the effects of NCTD on GBM cells. We found that NCTD dose-dependently increased SENP6 protein, but not messenger RNA (mRNA), in GBM cells, resulting in the suppression of cell invasion. Depletion of SENP6 in GBM cells significantly attenuated the NCTD-induced suppression of GBM cell invasion, while overexpression of SENP6 in GBM cells mimicked the effects of NCTD on cell invasion. Moreover, NCTD dose-dependently decreased the levels of microRNA-655 (miR-655), which bound to 3′-UTR of SENP6 mRNA to inhibit its translation. Overexpression of miR-655 decreased SENP6 in GBM cells, while depletion of miR-655 increased SENP6 protein in GBM cells. Taken together, our data demonstrates a previously unappreciated control of NCTD to suppress GBM cell invasion through modulation of miR-655-regulated SENP6 protein translation.
KeywordsNorcantharidin (NCTD) Glioblastoma multiforme (GBM) SENP6 miR-655
This work has been supported by the Program for Excellent Talents in Liaoning Province in China (NO. LJQ2013088).
Compliance with ethical standards
All experiments were carried out in strict accordance with the regulations of the Guide for experimental research issued by Liaoning Medical University. The protocol was approved by the Institutional Animal Care and Use Committee of the Liaoning Medical University.
Conflicts of interest
- 18.Li XP, Jing W, Sun JJ, Liu ZY, Zhang JT, Sun W, et al. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo. BMC Cancer. 2015;15:527.CrossRefPubMedPubMedCentralGoogle Scholar